CompletedPhase 2NCT00084318
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Paul M. Harari, MDUniversity of Wisconsin, Madison
- Intervention
- cetuximab(biological)
- Enrollment
- 238 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2016
Study locations (30)
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Arizona Oncology Services Foundation, Phoenix, Arizona, United States
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn, Scottsdale, Arizona, United States
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea, Scottsdale, Arizona, United States
- Auburn Radiation Oncology, Auburn, California, United States
- Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
- Radiation Oncology Centers - Cameron Park, Cameron Park, California, United States
- Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
- Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
- Providence Holy Cross Cancer Center, Mission Hills, California, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- Radiation Oncology Center - Roseville, Roseville, California, United States
- Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00084318 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →